Skip to content

Exercise and Arterial Stiffness in Systemic Lupus Erythematosus

Effects of an Aerobic Exercise Intervention Program on Arterial Stiffness and Inflammation in Women With Systemic Lupus Erythematosus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03107442
Acronym
EJERCITALES
Enrollment
58
Registered
2017-04-11
Start date
2017-04-12
Completion date
2017-07-21
Last updated
2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Keywords

Arterial stiffness, Markers of Inflammation, Exercise, Physical fitness, Cardiovascular risk, Autoimmune diseases

Brief summary

Patients with Systemic Lupus Erythematosus (SLE) have increased arterial stiffness, which leads to cardiovascular diseases (CVD) of arteriosclerotic origin, which are the main cause of mortality in these patients. Exercise is a modifiable factor that reduces cardiovascular mortality and associated risk factors in the general population. Preliminary studies suggest that exercise may improve endothelial function and lipid profile in patients with SLE. However, whether meeting the international physical activity guidelines from the American College of Sports Medicine (ACSM; i.e. ≥150 min / week of moderate to vigorous intensity physical activity) can improve arterial stiffness (subclinical atherosclerosis marker) and inflammation is unknown. The primary aim of this study is to assess the effect of an exercise program based on meeting the ACSM physical activity guidelines on arterial stiffness and inflammation in patients with SLE. The secondary aim is to assess the effect of an exercise program based on meeting the ACSM physical activity guidelines on endothelial function, oxidative stress, as well as other cardiometabolic risk factors, physical fitness, health-related quality of life, and other psychosocial outcomes. Our hypothesis is that meeting the ACSM guidelines will improve arterial stiffness and inflammation in patients with SLE. The study is a non-randomized clinical trial. To minimize selection bias, participants in the intervention and control groups will be matched by age, BMI, and disease activity (SLEDAI), which are important contributors to arterial stiffness.

Detailed description

2\. Design and Protocol Registration This non-randomized controlled trial was registered at clinicaltrials.gov \[NCT03107442\] on 11 April 2017, before the enrolment of participants started (i.e., on 12 April), and no deviations occurred regarding the primary outcome and the secondary outcomes analyzed here. 3\. Setting and Eligibility Criteria Participants were recruited from the Systemic Autoimmune Diseases Unit of the Virgen de las Nieves and the San Cecilio University Hospitals. Women with a diagnosis of SLE according to the ACR criteria \[26\], a follow-up of 12 months, clinical and treatment stability during the previous six months, and not performing regular exercise (defined as 60 min/week of structured exercise) were included. Exclusion criteria were to have been under biological treatment in the previous six months or to need a prednisone dose of \>10 mg/day; a background of CVD in the previous year; to present contraindications to perform exercise; other associated rheumatic conditions; pregnancy; active acute or chronic infection; neoplasms; acute renal failure; cardiac or pulmonary involvement; body mass index (BMI) \>35; or not being able to read, understand, and sign written informed consent. All participants received detailed information about the study procedures, and signed written informed consent. The Research Ethics Committee of Granada approved the protocol on 11 November 2016 (reference No.: 10/2016). 4\. Procedures A telephone screening was conducted. Potentially eligible participants were invited to a personal screening and, if included, day 1 of the baseline examination was performed. The baseline examination comprised two assessment days. On day 1, pulse wave velocity (PWV) was assessed. Thereafter, cardiorespiratory fitness testing was performed, and socio-demographic and clinical information was collected. On day 2 (i.e., between two and four days after day 1), 8-h fasting blood samples were collected between 8:00 a.m. and 10:00 a.m. This article follows the TREND statement for improving the reporting of non-randomized experiments of behavioral and public health interventions (downloadable at EQUATOR Network: https://goo.gl/ZSyLrj; Supplementary Table S1) \[27\]. The funding source had no role in the study. 5\. Methods 5.1. Interventions 5.1. 1. Exercise Group To maximize transparency and replicability, the exercise program described in this manuscript follows the Consensus on Exercise Reporting Template (CERT; Supplementary Table S2) \[28\]. The patients assigned to exercise performed two 75-min sessions per week during a total of 12 weeks (i.e., 24 sessions) of moderate to vigorous intensity aerobic exercise on a treadmill (BH, Serie i.RC12 Dual, Vitoria-Gasteiz, Spain) from 24 April to 14 July 2017. The sessions took place in a quiet room of the Virgen de las Nieves Hospital, Granada (Spain). All sessions were performed in groups of a maximum of five persons (depending on the patients' schedule preferences) and were supervised by both exercise professionals with a degree in Sports Sciences and residents from the Internal Medicine Department. Attendance at the sessions was registered daily and patients were contacted upon any missing session to ask for the reason and motivate them to replace it on an alternative day of the same week. Adherence to exercise is reported as the median attendance frequency and the proportion of patients attending \>75% (i.e., 18 sessions; the minimum pre-defined attendance to assess efficacy) and \>90% of the sessions. All the sessions began with a warm-up comprising 3-4 min of activation on the treadmill at about 35-40% of the heart rate reserve (HRR) and 3-4 min of active stretching of major muscle groups, and ended with a cool down phase of static stretching of major muscle groups and relaxation. Exercise was individually prescribed to represent moderate-to-vigorous intensity, with training intensity ranging from 40% to 75% of each patient's HRR. The maximum heart rate (HRmax) was estimated with the formula by Tanaka et al. (HRmax = 208 x (0.7 x age)) \[29\]. The training (or target) heart rate (tHR) was calculated with the formula tHR = HRrest + (%HRR). Heart rate was continuously monitored during all sessions (Polar V800, Kempele, Finland). We used the session rating of perceived exertion (RPE) as a measure of subjective training load \[30\], and the feeling scale to assess positive affective responses experienced before and after each session \[31\]. The starting level was specific for each individual according to her previous exercise experience and physical fitness. During the first half of the program, only continuous exercise was performed so that the patients got used to the treadmill and felt confident at increasing intensities. Continuous sessions comprised several bouts of exertion at constant intensity, followed by a couple of minutes of recovery (i.e., rest) to drink water. During month 2, there were alternated continuous and interval sessions, and at month 3, the patients undertook interval training sessions, where there were periods of lower and periods of higher intensity efforts followed by some minutes of rest for hydration (Table 1). The progression in volume and/or intensity was patient-limited and was undertaken by increasing the treadmill speed (first) or inclination according to the symptoms and perceived exertion. There were no home-based or non-exercise components within this intervention. However, if a participant was eventually not able to attend a particular session, we provided her with a heart rate monitor and allowed recovery of that session out of the Hospital (a total of seven sessions were recovered in this fashion). Finally, the exercise intensity progressions had to be slightly modified from the initial plan. For instance, several patients perceived a 5% HRR intensity increase (i.e., from one week to another) as very heavy and difficult-to-follow. Consequently, there were weeks in which exercise intensity increased by 2.5% instead of 5% (Table 1). 5.1.2. Control Group After the baseline evaluation, the SLE patients assigned to the (usual care) control group received verbal information about a healthy lifestyle, including physical activity guidelines and basic nutritional information. 5.2. Outcome Measures Primary Outcome Measure: Arterial Stiffness Arterial stiffness was assessed in a sitting position by PWV \[9\], using the Mobil-O-Graph® 24 h pulse wave analysis monitor (IEM GmbH, Stolberg, Germany), whose operation is based on oscillometry recorded by a blood pressure cuff placed on the brachial artery. The coefficient of variation (CV) of Mobil-O-Graph for consecutive PWV analyses is 3.4% and its intraclass correlation coefficient is 0.98 \[0.96-0.99\] \[32\]. This device has been largely shown to be valid and reliable for measuring PWV and central blood pressure in different populations \[33,34\], meets the accuracy requirements of the British Hypertension Society (BHS) standard \[35\], and can be recommended for clinical use \[36\]. Secondary Outcome Measures Blood Samples and Biochemical Analyses Fasting blood specimens for biochemical and immunological tests were collected and routinely processed by the central laboratory of our hospital. Among other measurements, they included lipids, insulin (BioRad, Marne-la-Coquette, France), and a routine biochemical profile. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated (HOMA-IR = glucose (mmol/L) insulin ( U/L)/22.5). Inflammatory Markers Serum high-sensitivity CRP was assessed by an immunoturbidimetric method using the ARCHITECT cSystems (MULTIGENT CRP Vario assay); the limit of quantitation was 0.2 mg/L and the upper limit for normal serum was 5 mg/L (coefficient of variation \<6%). Interleukin 6 and TNF- , as well as myeloperoxidase (MPO; as marker of oxidative stress), were measured in plasma. Serum was initially separated by centrifugation and stored at 70 C. Bioserum concentrations of IL-6/TNF- (pg/mL) and MPO (ng/mL) were measured by an immunoradiometric assay using commercial kits (MILLIPLEX MAP Kit Human High Sensitivity T Cell Magnetic Bead Panel (HSTMAG-28SK) and Human Cardiovascular Disease Magnetic Bead Panel 2 (HCVD2MAG-67K)), Millipore) following the manufacturer's instructions. Quantitative data were obtained by using the Luminex-200 system (Luminex Corporation, Austin, TX, USA), and data analysis was performed on XPonent 3.1 software (Austin, TX, USA). The detections limits were 0.73 pg/mL for IL-6, 0.43 pg/mL for TNF-a, and 0.024 ng/mL for MPO. Cardiorespiratory Fitness Cardiorespiratory fitness was assessed with the Bruce submaximal treadmill protocol \[37\]. The test comprised five increasing workload stages of 3 min each (stage 1: 2.7 km/h and 10% inclination; stage 2: 4 km/h and 12% inclination; stage 3: 5.5 km/h and 14% inclination; stage 4: 6.8 km/h and 16% inclination; stage 5: 8 km/h and 18% inclination). The test concluded when the participant achieved 85% of the individual's HRmax, as estimated with the formula by Tanaka et al. \[29\]. As validated SLE-specific formulas to estimate VO2max are not available, we used the total time to reach 85% HRmax as the outcome of interest. Other Measurements All participants filled out a socio-demographic and clinical data questionnaire. Height (cm) was measured using a height gauge, weight (kg) with a bioimpedance device (InBody R20, Biospace, Seoul, Korea), and body mass index (BMI) was calculated (kg/m2). Blood pressure was measured with Mobil-O-Graph (IEM GmbH, Stolberg, Germany) \[36\]. Disease activity was assessed through the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI, range 0-105 where a higher score indicates higher degree of disease activity). Physical activity was self-reported at baseline and at week 12 with the International Physical Activity Questionnaire \[38\]. Sample Size The sample size was calculated for the primary outcome (i.e., PWV). Ashor et al. found an average effect of aerobic exercise on PWV of 0.63 m/s in adults aged 18 years \[21\]. A total of 52 patients (26 per group) were needed to detect an effect of 0.63 (SD 0.75) m/s, with a power of 85% and an error of 0.05. Anticipating a maximum loss to follow-up of 15%, we aimed at recruiting a total of 60 patients. Treatment Allocation and Blinding Randomization was not feasible because more than half of the patients who regularly attend the Autoimmune Disease Units lived far from the Hospital and were not able to attend twice per week in case of being randomized to exercise. Therefore, participants from the city of Granada were included in the exercise group and participants living outside Granada were included in the control group. To minimize potential selection bias, we aimed to match the groups by age ( 2 years), BMI ( 1 kg/m2), and SLEDAI ( 1 unit). The data analyzer was blinded to the patient allocation.

Interventions

BEHAVIORALAerobic exercise

12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.

Sponsors

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Systemic Lupus Erythematosus (SLE) according to the American College of Rheumatology criteria (presenting at least 4 classification criteria). * Follow-up of at least 12 months at our Unit. * Clinical and treatment stability during the 6 months prior to the study. * Not performing regular exercise (defined as \< 60min/week of structured exercise)

Exclusion criteria

* Biological treatment in the previous 6 months or to need prednisone dosis \>10 mg/day. * Background of clinical cardiovascular disease in the last year. * To present contraindications to perform exercise. * Other associated rheumatic conditions. * Pregnancy. * Acute renal failure. * Cardiac or pulmonary involvement. * Body Mass Index \> 35 * Not being able to read, understand and sign written informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Arterial Stiffnessvalue at 12 weeks minus value at baselinePulse wave velocity assessed with Mobil-OGraph ® 24h pulse wave analysis monitor (IEM GmbH, Stolberg, Germany)

Secondary

MeasureTime frameDescription
GlucoseChange from baseline to week 12Blood glucose levels
InsulinChange from baseline to week 12Blood insulin levels
Homeostasis Model Assessment of Insulin ResistanceChange from baseline to week 12Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Glycated HemoglobinChange from baseline to week 12Glycated hemoglobin (HbA1c %) obtained from blood sample
LipidChange from baseline to week 12Triglycerides
Cardiorespiratory FitnessChange from baseline to week 12Assessed by the modified Bruce Test on a treadmill. The test comprised five increasing workload stages of 3 min each (stage 1: 2.7 km/h and 10% inclination; stage 2: 4 km/h and 12% inclination; stage 3: 5.5 km/h and 14% inclination; stage 4: 6.8 km/h and 16% inclination; stage 5: 8 km/h and 18% inclination). The test concluded when the participant achieved 85% of the individual's HRmax
Muscle StrengthChange from baseline to week 12Assessed by isometric handgrip dynamometry (hand grip strength test \[TKK 5401, Takei Scientific Instruments, Tokyo, Japan\]
FlexibilityChange from baseline to week 12Assessed by the back scratch test (from the Senior Fitness Test battery)
Waist and Hip CircumferenceChange from baseline to week 12Waist and hip circumferences (cm) and ratio
Markers of InflammationChange from baseline to week 12High sensitivity C-Reactive Protein (hs-CRP)
CoagulationChange from baseline to week 12Fibrinogen in Blood
Renal FunctionChange from baseline to week 12Creatinine in blood sample
Health-related Quality of LifeChange from baseline to week 12The Spanish version of the 36-item Short-Form Health Survey (SF-36) was used to assess HRQoL. This questionnaire is validated for patients with SLE and it assesses eight health dimensions that define two global domains: the physical and mental component scales (PCS and MCS, respectively). Only the global domains were used for the present work, which scores range from 0 (worst possible health status) to 100 (the best possible health status).
DepressionChange from baseline to week 12Assessed by the Beck Depression Inventory second edition (BDI-II). Depressive symptomatology was assessed through the Beck Depression Inventory-second edition (BDI-II) \[41\]. This questionnaire has been used extensively in research, including SLE . It is a 21-item self-report measure where, according to how patients felt during the past 2 weeks, each depressive symptom is rated from 0 (not present) to 3 (severe). The BDI-II provides an overall score (0-63) where higher score indicates higher depressive symptomatology.
FatigueChange from baseline to week 12Fatigue was assessed with the Multidimensional Fatigue Inventory (MFI), which is a well-established instrument previously used in SLE. This questionnaire includes 5 subscales of fatigue severity: general, physical, and mental fatigue as well as reduced activity, and reduced motivation. Each subscale consists of four items ranging from 4 to 20, with higher scores indicating greater fatigue on that subscale.
Sleep QualityChange from baseline to week 12Sleep quality over the last month interval was assessed with the Pittsburg Sleep Quality Index (PSQI), a widely-used instrument in SLE. This questionnaire is composed of 19 questions addressing a variety of factors related to sleep quality. The sleep quality global score is the sum of all components, that ranges from 0 to 21, with higher scores indicating worse sleep quality.
Sedentary BehaviorChange from baseline to week 12Assessed by the Sedentary Behavior Questionnaire (SBQ). Assesses the amount of time spent on nine different behaviours.
Adherence to the Mediterranean DietChange from baseline to week 12Adherence to the Mediterranean diet was estimated using the Mediterranean Diet Score. It consists of 11 items including whole grains, fruits, vegetables, potatoes, legumes, fish, poultry, dairy products (such as cheese, yogurt, and milk), red meats and their derivatives, olive oil, and red wine. Based on the portions the patients had consumed, the foods were scored from 0 to 5 (according to their position in the Mediterranean Diet pyramid). Total score ranges from 0 to 55, where higher scores indicate higher adherence to the Mediterranean diet and greater diet quality.
Perceived StressChange from baseline to week 12Assessed by the Perceived Stress Scale (PSS). Psychological stress was measured with the Perceived Stress Scale (PSS), a 14-item self-report global measure designed to assess the degree to which situations in one's life are appraised as stressful \[35\]. The PSS have shown to be a valid and reliable measure in patients with SLE \[36\]. According to how patients felt during the last month, each item is rated from 0 (never) to 4 (very often). The PSS provides a single overall score (0-56) where higher score represents greater perceived stress.
BMIChange from baseline to week 12Body Mass Index

Countries

Spain

Participant flow

Participants by arm

ArmCount
Exercise
12-weeks aerobic exercise intervention Aerobic exercise: 12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
26
Control
Usual care, with recommendations for a healthy lifestyle.
32
Total58

Baseline characteristics

CharacteristicExerciseControlTotal
Age, Continuous43.0 years
STANDARD_DEVIATION 15.1
44.8 years
STANDARD_DEVIATION 13.1
44.0 years
STANDARD_DEVIATION 13.9
Body Mass Index (BMI)25.9 kg/m^2
STANDARD_DEVIATION 3.4
24.7 kg/m^2
STANDARD_DEVIATION 5.6
25.2 kg/m^2
STANDARD_DEVIATION 4.7
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
26 Participants32 Participants58 Participants
Region of Enrollment
Spain
26 Participants32 Participants58 Participants
Sex: Female, Male
Female
26 Participants32 Participants58 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 260 / 32
other
Total, other adverse events
0 / 260 / 32
serious
Total, serious adverse events
0 / 260 / 32

Outcome results

Primary

Arterial Stiffness

Pulse wave velocity assessed with Mobil-OGraph ® 24h pulse wave analysis monitor (IEM GmbH, Stolberg, Germany)

Time frame: value at 12 weeks minus value at baseline

ArmMeasureValue (MEDIAN)Dispersion
ExerciseArterial Stiffness-0.26 m/sStandard Error 0.14
ControlArterial Stiffness-0.22 m/sStandard Error 0.13
Secondary

Adherence to the Mediterranean Diet

Adherence to the Mediterranean diet was estimated using the Mediterranean Diet Score. It consists of 11 items including whole grains, fruits, vegetables, potatoes, legumes, fish, poultry, dairy products (such as cheese, yogurt, and milk), red meats and their derivatives, olive oil, and red wine. Based on the portions the patients had consumed, the foods were scored from 0 to 5 (according to their position in the Mediterranean Diet pyramid). Total score ranges from 0 to 55, where higher scores indicate higher adherence to the Mediterranean diet and greater diet quality.

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseAdherence to the Mediterranean Diet-1.61 score on a scaleStandard Error 0.01
ControlAdherence to the Mediterranean Diet0.71 score on a scaleStandard Error 0.04
Secondary

BMI

Body Mass Index

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseBMI0.3 kg/m^2Standard Error 0.03
ControlBMI0.51 kg/m^2Standard Error 0.1
Secondary

Cardiorespiratory Fitness

Assessed by the modified Bruce Test on a treadmill. The test comprised five increasing workload stages of 3 min each (stage 1: 2.7 km/h and 10% inclination; stage 2: 4 km/h and 12% inclination; stage 3: 5.5 km/h and 14% inclination; stage 4: 6.8 km/h and 16% inclination; stage 5: 8 km/h and 18% inclination). The test concluded when the participant achieved 85% of the individual's HRmax

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseCardiorespiratory Fitness2.622 minutesStandard Error 0.41
ControlCardiorespiratory Fitness0.43 minutesStandard Error 0.45
Secondary

Coagulation

Fibrinogen in Blood

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseCoagulation29.23 mg/dLStandard Error 13.99
ControlCoagulation38.1 mg/dLStandard Error 10.03
Secondary

Depression

Assessed by the Beck Depression Inventory second edition (BDI-II). Depressive symptomatology was assessed through the Beck Depression Inventory-second edition (BDI-II) \[41\]. This questionnaire has been used extensively in research, including SLE . It is a 21-item self-report measure where, according to how patients felt during the past 2 weeks, each depressive symptom is rated from 0 (not present) to 3 (severe). The BDI-II provides an overall score (0-63) where higher score indicates higher depressive symptomatology.

Time frame: Change from baseline to week 12

ArmMeasureValue (MEDIAN)Dispersion
ExerciseDepression-3.32 score on a scaleStandard Error 1.74
ControlDepression-1.32 score on a scaleStandard Error 1.56
Secondary

Fatigue

Fatigue was assessed with the Multidimensional Fatigue Inventory (MFI), which is a well-established instrument previously used in SLE. This questionnaire includes 5 subscales of fatigue severity: general, physical, and mental fatigue as well as reduced activity, and reduced motivation. Each subscale consists of four items ranging from 4 to 20, with higher scores indicating greater fatigue on that subscale.

Time frame: Change from baseline to week 12

ArmMeasureValue (MEDIAN)Dispersion
ExerciseFatigue-3 units on a scaleStandard Error 0.74
ControlFatigue-0.01 units on a scaleStandard Error 0.66
Secondary

Flexibility

Assessed by the back scratch test (from the Senior Fitness Test battery)

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseFlexibility-0.03 cmStandard Error 0.13
ControlFlexibility-2.66 cmStandard Error 0.05
Secondary

Glucose

Blood glucose levels

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseGlucose-3.12 mg/dLStandard Error 0.69
ControlGlucose4.47 mg/dLStandard Error 3.77
Secondary

Glycated Hemoglobin

Glycated hemoglobin (HbA1c %) obtained from blood sample

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseGlycated Hemoglobin-0.02 percentage hemoglobinStandard Error 0.003
ControlGlycated Hemoglobin0.10 percentage hemoglobinStandard Error 0.02
Secondary

Health-related Quality of Life

The Spanish version of the 36-item Short-Form Health Survey (SF-36) was used to assess HRQoL. This questionnaire is validated for patients with SLE and it assesses eight health dimensions that define two global domains: the physical and mental component scales (PCS and MCS, respectively). Only the global domains were used for the present work, which scores range from 0 (worst possible health status) to 100 (the best possible health status).

Time frame: Change from baseline to week 12

ArmMeasureValue (MEDIAN)Dispersion
ExerciseHealth-related Quality of Life3.82 pointsStandard Error 2.07
ControlHealth-related Quality of Life0.21 pointsStandard Error 1.63
Secondary

Homeostasis Model Assessment of Insulin Resistance

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseHomeostasis Model Assessment of Insulin Resistance-0.1 HOMA IndexStandard Error 0.03
ControlHomeostasis Model Assessment of Insulin Resistance0.22 HOMA IndexStandard Error 0.07
Secondary

Insulin

Blood insulin levels

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseInsulin-0.32 microUI/mLStandard Error 0.09
ControlInsulin0.30 microUI/mLStandard Error 0.16
Secondary

Lipid

Triglycerides

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseLipid-2.72 mg/dLStandard Error 1.86
ControlLipid3.5 mg/dLStandard Error 0.62
Secondary

Markers of Inflammation

High sensitivity C-Reactive Protein (hs-CRP)

Time frame: Change from baseline to week 12

ArmMeasureValue (MEDIAN)Dispersion
ExerciseMarkers of Inflammation0.17 mg/LStandard Error 0.59
ControlMarkers of Inflammation-0.24 mg/LStandard Error 0.55
Secondary

Muscle Strength

Assessed by isometric handgrip dynamometry (hand grip strength test \[TKK 5401, Takei Scientific Instruments, Tokyo, Japan\]

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseMuscle Strength0.91 KgStandard Error 0.33
ControlMuscle Strength0.27 KgStandard Error 0.07
Secondary

Perceived Stress

Assessed by the Perceived Stress Scale (PSS). Psychological stress was measured with the Perceived Stress Scale (PSS), a 14-item self-report global measure designed to assess the degree to which situations in one's life are appraised as stressful \[35\]. The PSS have shown to be a valid and reliable measure in patients with SLE \[36\]. According to how patients felt during the last month, each item is rated from 0 (never) to 4 (very often). The PSS provides a single overall score (0-56) where higher score represents greater perceived stress.

Time frame: Change from baseline to week 12

ArmMeasureValue (MEDIAN)Dispersion
ExercisePerceived Stress-1.6 units on a scaleStandard Error 1.13
ControlPerceived Stress-1.2 units on a scaleStandard Error 1
Secondary

Renal Function

Creatinine in blood sample

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseRenal Function0.01 mg/dLStandard Error 0.1
ControlRenal Function-0.08 mg/dLStandard Error 0.03
Secondary

Sedentary Behavior

Assessed by the Sedentary Behavior Questionnaire (SBQ). Assesses the amount of time spent on nine different behaviours.

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseSedentary Behavior129 min/weekStandard Error 3.67
ControlSedentary Behavior105 min/weekStandard Error 10.83
Secondary

Sleep Quality

Sleep quality over the last month interval was assessed with the Pittsburg Sleep Quality Index (PSQI), a widely-used instrument in SLE. This questionnaire is composed of 19 questions addressing a variety of factors related to sleep quality. The sleep quality global score is the sum of all components, that ranges from 0 to 21, with higher scores indicating worse sleep quality.

Time frame: Change from baseline to week 12

ArmMeasureValue (MEDIAN)Dispersion
ExerciseSleep Quality-0.96 units on a scaleStandard Error 0.84
ControlSleep Quality-0.32 units on a scaleStandard Error 0.65
Secondary

Waist and Hip Circumference

Waist and hip circumferences (cm) and ratio

Time frame: Change from baseline to week 12

ArmMeasureValue (MEAN)Dispersion
ExerciseWaist and Hip Circumference0.03 Waist to hip ratioStandard Error 0.2
ControlWaist and Hip Circumference0.02 Waist to hip ratioStandard Error 0.006

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026